• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

2024 AAD Annual Meeting Recap: Day 2


Catch up on coverage from the second day of the 2024 American Academy of Dermatology Annual Meeting.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Peter Lio, MD, FAAD: Navigating Dietary Triggers in Urticaria and Atopic Dermatitis

Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."

Managing Ichthyosis in the General Dermatology Office

Christopher Bunick, MD, PhD, provides tips for the general dermatologist to treat ichthyosis and shares data on TMB-001 in development for ichthyosis.

Acne and Rosacea Pearls With Jim Del Rosso, DO, FAAD

The American Acne and Rosacea Society welcomed Del Rosso as its new president and he shared key takeaways from his AAD sessions.

Late-Breaking Data: Upadacitinib for Vitiligo Achieves Skin Repigmentation Through Week 52

Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.

Making Psoriasis Treatment More Accessible: LITE Study Shows Home Phototherapy Success

In an AAD late-breaking research session, Joel Gelfand, MD, MSCE, FAAD, presented in-depth results of the LITE Study.

Lessons From Boston Medical Center’s Coping Clinic

Dermatologists are able to connect pediatric patients to psychology clinicians for multidisciplinary care under one roof.

Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult-to-Treat HS After Failed TNF Therapy

Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.

The Impact of Atopic Dermatitis on Childhood Growth: Insights from the PEDISTAD Study

The international observational study aims to understand how moderate to severe AD affects children under 12 years of age, particularly in terms of height, weight, and BMI.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.